Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 2/20 | 0.50 |
| ▸ | RARG | P13631 | 2/20 | 0.50 |
| ▸ | RARA | P10276 | 1/20 | 0.50 |
| ▸ | HSPA9 | P38646 | 4/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | HTR5A | P47898 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15304427 | 0.89 | RARB (0.42) | RARBRARGRARAHSPA9CYP1A2 | |
| SCHEMBL428286 | 0.85 | RARB (0.50) | RARBRARGRARAHSPA9CYP1A2 | |
| SCHEMBL1607884 | 0.81 | CYP1A2 (0.41) | RARBRARGRARACYP1A2POLB | |
| SCHEMBL19260277 | 0.80 | HTR2A (0.50) | RARBRARGRARAHSPA9AR | |
| SCHEMBL9057990 | 0.80 | RARB (0.49) | RARBRARGRARAHSPA9AR | |
| SCHEMBL1396642 | 0.80 | RARB (0.49) | RARBRARGRARAHSPA9AR | |
| SCHEMBL6325616 | 0.80 | RARB (0.49) | RARBRARGRARAHSPA9CYP1A2 | |
| SCHEMBL19859121 | 0.80 | RARB (0.49) | RARBRARGRARAHSPA9AR | |
| SCHEMBL23714634 | 0.78 | RARB (0.36) | RARBRARGRARAHSPA9CYP1A2 | |
| SCHEMBL3794066 | 0.77 | HSPA9 (0.49) | RARBRARGRARAHSPA9AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11833203-B2 | Synthetic retinoids (in cell modulation) | UNIVERSITY OF DURHAM | 2023-12-05 | — | — | US | disclosed |
| US-11324825-B2 | Synthetic retinoids (in cell modulation) | UNIVERSITY OF DURHAM | 2022-05-10 | — | — | US | disclosed |
| WO-2021155316-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2021-08-05 | — | — | WO | disclosed |
| WO-2021102332-A1 | TGFBETAR2 INHIBITOR-LRRC15 ANTIBODY CONJUGATES AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. (US) | 2021-05-27 | — | — | WO | disclosed |
| US-20190209684-A1 | Synthetic Retinoids (in Cell Modulation) | UNIVERSITY OF DURHAM (GB) | 2019-07-11 | — | — | US | disclosed |
| US-20190209685-A1 | SYNTHETIC RETINOIDS (IN CELL MODULATION) | UNIVERSITY OF DURHAM (GB) | 2019-07-11 | — | — | US | disclosed |
| WO-2018029473-A1 | SYNTHETIC RETINOIDS (IN CELL MODULATION) | UNIVERSITY OF DURHAM (GB) | 2018-02-15 | — | — | WO | disclosed |
| US-7923579-B2 | Tricyclic hydroxamate and benzamide derivatives, compositions and methods | EXONHIT THERAPEUTICS S.A. (FR) | 2011-04-12 | — | — | US | disclosed |
| WO-2010129467-A1 | COMPOUNDS AND METHODS FOR INHIBITION OF RENIN, AND INDICATIONS THEREFOR | PLEXXIKON, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
| WO-2010129467-A1 | COMPOUNDS AND METHODS FOR INHIBITION OF RENIN, AND INDICATIONS THEREFOR | PLEXXIKON, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
| EP-1692097-B1 | TRICYCLIC HYDROXAMATE AND BENZAMIDE DERIVATIVES, COMPOSITIONS AND METHODS | EXONHIT THERAPEUTICS SA (FR) | 2009-09-02 | — | — | EP | disclosed |
| US-20070129368-A1 | Tricyclic hydroxamate and benzamide derivatives, compositions and methods | EXONHIT THERAPEUTICS S.A. (FR) | 2007-06-07 | — | — | US | disclosed |
| WO-2005058803-A1 | TRICYCLIC HYDROXAMATE AND BENZAMIDE DERIVATIVES, COMPOSITIONS AND METHODS | EXONHIT THERAPEUTICS SA (FR) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11833203-B2 | Synthetic retinoids (in cell modulation) | RARA, RARB, RXRA | RARB 2/4885RARG 4/4885RARA 1/4885 |
| US-20070129368-A1 | Tricyclic hydroxamate and benzamide derivatives, compositions and methods | HDAC5, HDAC1, HDAC2 | RARB 998/4885RARG 904/4885RARA 1012/4885 |
| US-11324825-B2 | Synthetic retinoids (in cell modulation) | RARA, RARB, RXRA | RARB 2/4885RARG 4/4885RARA 1/4885 |
| US-20190209685-A1 | SYNTHETIC RETINOIDS (IN CELL MODULATION) | RARA, RARB, RXRA | RARB 2/4885RARG 4/4885RARA 1/4885 |
| US-20190209684-A1 | Synthetic Retinoids (in Cell Modulation) | RARA, RARB, RXRA | RARB 2/4885RARG 4/4885RARA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.